WZWeiqi Zhang

Weiqi Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Weiqi Zhang has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Antibody-Peptide Assembly Conjugates Coordinate TREM2 and PD-1 Blockade for Macrophage-Centred Antitumour Immunity in Triple-Negative Breast Cancer

    by Weiqi Zhang, Yinghua Zeng, Yuxin Zhang, Haopeng Liu, Jingyue Pan, Yumu Liu, Yongyu Chen, Wenqing Zhu, Yongqi Ren, Yan He, et al.

    Immunosuppressive tumour-associated macrophages (TAMs) constrain the efficacy of immunotherapy in triple-negative breast cancer (TNBC), yet therapeutic systems that concurrently disrupt complementary macrophage-centred checkpoints remain scarce. Here we report antibody-peptide assembly conjugates (APACs), which integrate an anti-TREM2 antibody with a self-assembling PD-1-blocking peptide within a single supramolecular construct. Integrated bulk, single-cell and spatial analyses of human breast tumours identified partially overlapping TREM2- and PD-1-expressing macrophage populations and a TREM2/PDCD1-associated TAM state characterized by immunoregulatory signalling, lipid-metabolic adaptation and attenuated phagocytic and antigen-processing programmes. Appending a phenylalanine-containing assembly motif to the PD-1-blocking peptide promoted the formation of β-sheet-enriched nanofibres, and this peptide-driven assembly behaviour was retained after bioorthogonal conjugation to the anti-TREM2 antibody. APACs redirected TAMs from lipid-supported oxidative respiration towards glycolysis, enhanced tumour-cell phagocytosis and antigen-specific CD8⁺ T-cell activation, and produced sustained, macrophage-dependent tumour control and reduced pulmonary and hepatic metastatic burden in syngeneic TNBC models. These findings establish a biologically guided supramolecular strategy that integrates TREM2-directed macrophage modulation with PD-1 blockade to coordinate innate and adaptive antitumour immunity within macrophage-rich TNBC niches.

  • Open Access

    An in-situ peptide-antibody self-assembly to block CD47 and CD24 signaling enhances macrophage-mediated phagocytosis and anti-tumor immune responses

    by Weiqi Zhang, Yinghua Zeng, Qiuqun Xiao, Yuanyuan Wu, Jiale Liu, Haocheng Wang, Yuting Luo, Jie Zhan, Ning Liao, Yanbin Cai

    Targeted immunomodulation for reactivating innate cells, especially macrophages, holds great promise to complement current adaptive immunotherapy. Nevertheless, there is still a lack of high-performance therapeutics for blocking macrophage phagocytosis checkpoint inhibitors in solid tumors. Herein, a peptide-antibody combo-supramolecular in situ assembled CD47 and CD24 bi-target inhibitor (PAC-SABI) is described, which undergoes biomimetic surface propagation on cancer cell membranes through ligand-receptor binding and enzyme-triggered reactions. By simultaneously blocking CD47 and CD24 signaling, PAC-SABI enhances the phagocytic ability of macrophages in vitro and in vivo, promoting anti-tumor responses in breast and pancreatic cancer mouse models. Moreover, building on the foundation of PAC-SABI-induced macrophage repolarization and increased CD8+ T cell tumor infiltration, sequential anti-PD-1 therapy further suppresses 4T1 tumor progression, prolonging survival rate. The in vivo construction of PAC-SABI-based nano-architectonics provides an efficient platform for bridging innate and adaptive immunity to maximize therapeutic potency.